drugset
drugset / Trial / NCT03899792

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792 ↗

Phase 1/2 Active not recruiting 36 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.

Timeline

Start
2019-06-13
Primary completion
2024-11-08
Completion
2029-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Selpercatinib Small molecule 160 mg Oral

Indications

fibrosarcoma infantile myofibromatosis medullary thyroid gland carcinoma thyroid gland papillary carcinoma